In order to identify an antibody that is specific for LEDGF/p75 and that could be used by IHC to assess the expression levels of this protein in cancer TMAs, we evaluated by immunoblotting the specificity of currently available anti-LEDGF antibodies. This evidence concerns the gene PSIP1 and cancer.